(MedPage Today) — The FDA fully approved iptacopan (Fabhalta) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, drugmaker Novartis announced on Friday. The complement inhibitor…
Source: MedPage Today — Headlines
